Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model.

Literature DB >> 7515609

Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model.

L D Condreay¹, R W Jansen, T F Powdrill, L C Johnson, D W Selleseth, M T Paff, S M Daluge, G R Painter, P A Furman, M N Ellis.

Abstract

A murine model was developed to investigate the in vivo activity of anti-hepatitis B virus (HBV) agents. Mice with subcutaneous tumors of HBV-producing 2.2.15 cells showed reductions in levels of HBV in serum and in intracellular levels of HBV when the mice were orally dosed with (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (FTC). No effects on tumor size or alpha-fetoprotein levels were observed. FTC can selectively inhibit HBV replication at nontoxic doses.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1994 PMID： 7515609 PMCID： PMC284508 DOI： 10.1128/AAC.38.3.616

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

21 in total

1. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.

Authors: M A Sells; M L Chen; G Acs
Journal: Proc Natl Acad Sci U S A Date: 1987-02 Impact factor: 11.205

2. Morphologic, immunohistochemical, and ultrastructural studies of the production of hepatitis B virus in vitro.

Authors: M A Gerber; M A Sells; M L Chen; S N Thung; S S Tabibzadeh; A Hood; G Acs
Journal: Lab Invest Date: 1988-08 Impact factor: 5.662

3. Effects of adenine arabinoside on serum and intrahepatic replicative forms of duck hepatitis B virus in chronic infection.

Authors: K Hirota; A H Sherker; M Omata; O Yokosuka; K Okuda
Journal: Hepatology Date: 1987 Jan-Feb Impact factor: 17.425

4. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

Authors: B B Knowles; C C Howe; D P Aden
Journal: Science Date: 1980-07-25 Impact factor: 47.728

5. Induction of drug metabolizing enzymes in human liver cell line Hep G2.

Authors: J R Dawson; D J Adams; C R Wolf
Journal: FEBS Lett Date: 1985-04-22 Impact factor: 4.124

6. Comparative morphology and tumourigenicity of human hepatocellular carcinoma cell lines in athymic rats and mice.

Authors: D Shouval; L Schuger; I S Levij; L M Reid; Z Neeman; D A Shafritz
Journal: Virchows Arch A Pathol Anat Histopathol Date: 1988

7. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions.

Authors: M A Sells; A Z Zelent; M Shvartsman; G Acs
Journal: J Virol Date: 1988-08 Impact factor: 5.103

8. Tumorigenicity and transcriptional modulation of c-myc and N-ras oncogenes in a human hepatoma cell line.

Authors: B E Huber; K L Dearfield; J R Williams; C A Heilman; S S Thorgeirsson
Journal: Cancer Res Date: 1985-09 Impact factor: 12.701

Review 9. The problem of antiviral therapy for chronic hepadnavirus infections.

Authors: W S Mason
Journal: J Hepatol Date: 1993 Impact factor: 25.083

10. Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks.

Authors: A H Sherker; K Hirota; M Omata; K Okuda
Journal: Gastroenterology Date: 1986-10 Impact factor: 22.682

11 in total

1. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

Authors: R G Gish; N W Y Leung; T L Wright; Huy Trinh; W Lang; H A Kessler; L Fang; L H Wang; J Delehanty; A Rigney; E Mondou; A Snow; F Rousseau
Journal: Antimicrob Agents Chemother Date: 2002-06 Impact factor: 5.191

2. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.

Authors: J M Cullen; S L Smith; M G Davis; S E Dunn; C Botteron; A Cecchi; D Linsey; D Linzey; L Frick; M T Paff; A Goulding; K Biron
Journal: Antimicrob Agents Chemother Date: 1997-10 Impact factor: 5.191

Review 3. Combination chemotherapy for hepatitis B virus: the path forward?

Authors: T Shaw; S Locarnini
Journal: Drugs Date: 2000-09 Impact factor: 9.546

4. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.

Authors: I Fourel; J M Cullen; J Saputelli; C E Aldrich; P Schaffer; D R Averett; J Pugh; W S Mason
Journal: J Virol Date: 1994-12 Impact factor: 5.103

5. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro.

Authors: K P Fischer; D L Tyrrell
Journal: Antimicrob Agents Chemother Date: 1996-08 Impact factor: 5.191

Review 6. Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors: P C Rensen; R L de Vrueh; T J van Berkel
Journal: Clin Pharmacokinet Date: 1996-08 Impact factor: 6.447

7. (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes.

Authors: L D Condreay; J P Condreay; R W Jansen; M T Paff; D R Averett
Journal: Antimicrob Agents Chemother Date: 1996-02 Impact factor: 5.191

8. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.

Authors: F Zoulim; E Dannaoui; C Borel; O Hantz; T S Lin; S H Liu; C Trépo; Y C Cheng
Journal: Antimicrob Agents Chemother Date: 1996-02 Impact factor: 5.191

9. Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol.

Authors: V Nair; M H St Clair; J E Reardon; H C Krasny; R J Hazen; M T Paff; L R Boone; M Tisdale; I Najera; R E Dornsife
Journal: Antimicrob Agents Chemother Date: 1995-09 Impact factor: 5.191

10. The Anti-hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-viremia SCID Mice.

Authors: Jia-Ming Chang; Kai-Ling Huang; Thomas Ta-Tung Yuan; Yiu-Kay Lai; Le-Mei Hung
Journal: Evid Based Complement Alternat Med Date: 2008-01-07 Impact factor: 2.629